lutetium Lu 177-DOTA-ABM-5G
Term · Oncology and biomedicine · MLC-T-ONC-014929
A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells.
| Identifier | MLC-T-ONC-014929 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | [177Lu]-DOTA-ABM-5G |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014929",
"term": "lutetium Lu 177-DOTA-ABM-5G",
"field": "Oncology and biomedicine",
"definition": "A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells.",
"synonyms": [
"[177Lu]-DOTA-ABM-5G"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-dota-abm-5g/"
}
Record 10,413 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.